HémopressineHemopressin (Hp, PVNFKFLSH)
A haemoglobin nonapeptide, a selective CB1 inverse agonist; its endogenous existence is contested.
C₅₃H₇₇N₁₃O₁₂
CAS 568588-77-2
- Family
- Endocannabinoid or related mediatorPeptide ligand
- Molar mass
- 1,088.30 g/mol
Updated on
In plain terms
Hemopressin is a small peptide fragment derived from haemoglobin, the pigment that carries oxygen in the blood. Its distinctive feature is that it blocks the CB1 receptor, the very one THC activates. Whether it really exists in the body remains disputed: the established endogenous form of this family is a longer peptide, RVD-hemopressin.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to Hémopressine: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Hémopressine.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Inverse agonistno measured value cited
Selective binding to CB1, effective blockade of its signalling with no effect on the other class A G-protein-coupled receptors (CB2 included) and suppression of the receptor's constitutive activity to the same extent as rimonabant (Heimann 2007); inhibition of agonist-induced receptor internalisation (Dodd 2010). No affinity value is published in these abstracts
Pharmacology
Hemopressin is a nonapeptide of sequence PVNFKFLSH, derived from the alpha chain of haemoglobin, which has held a singular place in the history of the endocannabinoid system: that of the first peptide ligand of the CB1 receptor. Identified in 2003 as a metallopeptidase substrate and named after its hypotensive effect in the anaesthetised rat (Rioli 2003), it was characterised in 2007 as a selective antagonist and inverse agonist of CB1, blocking the receptor's constitutive activity as well as rimonabant does, without acting on the other family-A G protein-coupled receptors, CB2 included, with antinociceptive effects by intrathecal, intraplantar and oral routes (Heimann 2007). In 2010 it proved able to inhibit CB1 internalisation and to reduce night-time food intake in rats and mice, an effect absent in mice lacking CB1 (Dodd 2010). This history calls for an important reservation, which this wiki states rather than hides: the fact that a peptide from a cytosolic protein acts on a receptor does not prove it is an endogenous mediator, which would require establishing its brain synthesis, its secretion at sufficient levels and the regulation of one or the other (Gelman & Fricker 2010). The documented endogenous peptide of this family is the extended form, RVD-hemopressin or pepcan-12, produced from the pro-peptide pepcan-23, a negative allosteric modulator of CB1 and a positive one of CB2 (Bauer 2012; Petrucci 2017), while hemopressin shows poor plasma stability and is not bioavailable to the brain (Glasmacher & Gertsch 2021). Hemopressin therefore remains a documented pharmacological tool whose status as a physiological mediator is not settled.
Key sources.
- Rioli et al. 2003, J Biol Chem: identification of the nonapeptide PVNFKFLSH, named hemopressin, and hypotensive effect in the rat (new tab)PMID 12500972
- Heimann et al. 2007, PNAS: hemopressin is an inverse agonist of the CB1 receptor (new tab)PMID 18077343
- Dodd et al. 2010, J Neurosci: hemopressin acts via CB1 to reduce food intake in the rat and the mouse (new tab)PMID 20505104
- Gelman & Fricker 2010, AAPS J: are hemopressin and other peptides from cytosolic proteins non-classical neuropeptides? (new tab)PMID 20383670
- Bauer et al. 2012, J Biol Chem: identification of the pepcan family, negative allosteric modulation of CB1 (new tab)PMID 22952224
- Petrucci et al. 2017, Sci Rep: pepcan-12 (RVD-hemopressin), a positive allosteric modulator of CB2 (new tab)PMID 28842619
- Glasmacher & Gertsch 2021, Adv Biol Regul: pepcan-23, the propeptide of RVD-haemopressin, and stability of haemopressins in the mouse (new tab)PMID 33799079
- Blais et al. 2005, Peptides: hypotensive effects of hemopressin and bradykinin in the rabbit, the rat and the mouse (new tab)PMID 16042973
- PubChem CID 44560117, hemopressin (sequence PVNFKFLSH) (new tab)
History
- Source
- A peptide fragment derived from haemoglobin, not a lipid molecule like the classical endocannabinoids. Its endogenous character is precisely the contested point. A review devoted to peptides from cytosolic proteins frames the problem in terms of criteria: to count as a neuropeptide-like mediator, such a peptide must be synthesised in the brain, secreted at levels sufficient to produce its effects, and its synthesis or secretion must be regulated; acting on a receptor is not enough (Gelman & Fricker 2010). Work on the pepcan family has moreover established that the documented endogenous peptide of this series is the form extended by three residues, RVD-hemopressin or pepcan-12, released from a pro-peptide, pepcan-23 (Bauer 2012; Glasmacher & Gertsch 2021); that form has its own entry. Hemopressin itself shows poor plasma stability and is not bioavailable to the brain (Glasmacher & Gertsch 2021).
Biosynthetic pathway
In vivo
Hemopressin corresponds to a fragment of the alpha chain of haemoglobin, released by proteolytic cleavage: this is a peptide-generating route, unrelated to the lipid pathway that produces anandamide or 2-AG from membrane phospholipids. The peptide was in fact discovered as a substrate of metallopeptidases of neuropeptide metabolism (Rioli 2003). For the extended form the lineage is established: pepcan-23 acts as a pro-peptide and releases RVD-hemopressin (Glasmacher & Gertsch 2021). Nothing equivalent is demonstrated for the nonapeptide, whose in vivo production route remains undetermined.
Legal framework
- European Union
No harmonised control at Union level and no listing in the schedules of the 1961 and 1971 United Nations conventions. The peptide has been the subject of no marketing authorisation application.
- France
No narcotic status: this is a peptide of biological origin, listed neither as a narcotic nor as a psychotropic substance (orders of 22 February 1990), and foreign to the benzo[c]chromene family covered by the ANSM decisions of June 2024. It has research-reagent status and does not circulate as a consumer product.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Endocannabinoid or related mediator › Peptide ligand
- Verification
Every fact on this entry was checked against its primary sources on 20 October 2026.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Rioli et al. 2003, J Biol Chem: identification of the nonapeptide PVNFKFLSH, named hemopressin, and hypotensive effect in the rat (new tab)PMID 12500972
- Heimann et al. 2007, PNAS: hemopressin is an inverse agonist of the CB1 receptor (new tab)PMID 18077343
- Dodd et al. 2010, J Neurosci: hemopressin acts via CB1 to reduce food intake in the rat and the mouse (new tab)PMID 20505104
- Gelman & Fricker 2010, AAPS J: are hemopressin and other peptides from cytosolic proteins non-classical neuropeptides? (new tab)PMID 20383670
- Bauer et al. 2012, J Biol Chem: identification of the pepcan family, negative allosteric modulation of CB1 (new tab)PMID 22952224
- Petrucci et al. 2017, Sci Rep: pepcan-12 (RVD-hemopressin), a positive allosteric modulator of CB2 (new tab)PMID 28842619
- Glasmacher & Gertsch 2021, Adv Biol Regul: pepcan-23, the propeptide of RVD-haemopressin, and stability of haemopressins in the mouse (new tab)PMID 33799079
- Blais et al. 2005, Peptides: hypotensive effects of hemopressin and bradykinin in the rabbit, the rat and the mouse (new tab)PMID 16042973
- PubChem CID 44560117, hemopressin (sequence PVNFKFLSH) (new tab)
Identifiers
Names
- Common name
- Hemopressin (Hp, PVNFKFLSH)
- Other names
- Hemopressin · Hp · PVNFKFLSH
Identifiers
- Formula
- C₅₃H₇₇N₁₃O₁₂
- CAS
- 568588-77-2
- PubChem CID
- 44560117(new tab)
- InChIKey
- DUTLYPZZJJBEAJ-QISMNGAHSA-N
- SMILES
- CC(C)
C[C@@H] (C(= O) N[C@@H] (CO) C(= O) N[C@@H] (CC1= CN= CN1) C(= O) O) NC(= O) [C@H] (CC2= CC= CC= C2) NC(= O) [C@H] (CCCCN) NC(= O) [C@H] (CC3= CC= CC= C3) NC(= O) [C@H] (CC(= O) N) NC(= O) [C@H] (C(C) C) NC(= O) [C@@H] 4CCCN4
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.